Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
All voices matter
Wegovy
Wegovy is only obesity drug linked to reduced death risk, BMJ analysis finds
A comprehensive analysis published in The BMJ on July 8 found that subcutaneous semaglutide — marketed as Wegovy — is the only obesity drug associated with reduced risks of death, heart attack, and heart failure, reinforcing Novo Nordisk's position in…
Novo Nordisk shares climb as oral Wegovy success offsets ransomware crisis
Novo Nordisk shares climbed more than 5% on Friday as investors looked past a ransomware incident and focused on the runaway success of the company's oral Wegovy pill and approaching Medicare coverage for GLP-1 weight-loss drugs.